PubRank

David A Fiellin

Author PubWeight™ 147.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007 5.68
2 Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011 3.15
3 Brief intervention for hazardous and harmful drinkers in the emergency department. Ann Emerg Med 2008 3.12
4 Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend 2007 2.99
5 A brief intervention reduces hazardous and harmful drinking in emergency department patients. Ann Emerg Med 2012 2.68
6 Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012 2.45
7 Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med 2007 2.38
8 Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007 2.38
9 Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis 2014 2.24
10 Gender and non-medical use of prescription opioids: results from a national US survey. Addiction 2007 2.15
11 An evidence-based guide to writing grant proposals for clinical research. Ann Intern Med 2005 2.13
12 Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005 2.05
13 The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med 2005 1.98
14 HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011 1.97
15 Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat 2008 1.89
16 The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005 1.72
17 A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 2006 1.62
18 Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr 2011 1.52
19 Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med 2002 1.52
20 The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med 2010 1.51
21 Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. J Clin Psychiatry 2015 1.51
22 Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med 2008 1.45
23 Federal plan for prescriber education on opioids misses opportunities. Ann Intern Med 2012 1.45
24 Women and opioid dependence treatment: office-based versus opioid treatment program-based care? Subst Abus 2007 1.42
25 Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans. Med Care 2006 1.41
26 Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2007 1.38
27 Food insecurity is associated with poor virologic response among HIV-infected patients receiving antiretroviral medications. J Gen Intern Med 2011 1.37
28 Increased hospital and emergency department utilization by individuals with recent criminal justice involvement: results of a national survey. J Gen Intern Med 2014 1.35
29 Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug Alcohol Depend 2013 1.33
30 Development and implementation of an emergency practitioner-performed brief intervention for hazardous and harmful drinkers in the emergency department. Acad Emerg Med 2005 1.31
31 The next therapeutic challenge in HIV: polypharmacy. Drugs Aging 2013 1.30
32 Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med 2008 1.30
33 Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend 2008 1.30
34 Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med 2007 1.27
35 Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med 2010 1.27
36 Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis 2005 1.24
37 Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug Alcohol Depend 2010 1.23
38 A research agenda for enhancing appropriate opioid prescribing in primary care. J Gen Intern Med 2013 1.23
39 The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 2006 1.21
40 Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis 2006 1.19
41 Provider satisfaction with office-based treatment of opioid dependence: a systematic review. Subst Abus 2005 1.18
42 Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr 2011 1.17
43 The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. J Acquir Immune Defic Syndr 2011 1.14
44 The effects of federal parity on substance use disorder treatment. Am J Manag Care 2014 1.13
45 The association between chronic pain and prescription drug abuse in Veterans. Pain Med 2009 1.12
46 Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr 2011 1.10
47 The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict 2010 1.10
48 Alcohol consumption and depressive symptoms over time: a longitudinal study of patients with and without HIV infection. Drug Alcohol Depend 2011 1.10
49 Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr 2011 1.09
50 A meta-analysis of the efficacy of nonphysician brief interventions for unhealthy alcohol use: implications for the patient-centered medical home. Am J Addict 2011 1.07
51 Evaluation of a combined online and in person training in the use of buprenorphine. Subst Abus 2006 1.04
52 Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend 2007 1.04
53 Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study. Am J Addict 2013 1.04
54 Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care 2011 1.03
55 Previous use of alcohol, cigarettes, and marijuana and subsequent abuse of prescription opioids in young adults. J Adolesc Health 2012 1.02
56 Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med 2012 1.02
57 Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr 2011 1.02
58 Opioids, chronic pain, and addiction in primary care. J Pain 2010 1.02
59 Comparing alcohol screening measures among HIV-infected and -uninfected men. Alcohol Clin Exp Res 2012 1.01
60 Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs 2008 1.01
61 Developing and implementing a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment (SBIRT). Subst Abus 2012 1.00
62 Training HIV physicians to prescribe buprenorphine for opioid dependence. Subst Abus 2006 1.00
63 Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend 2008 1.00
64 Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs 2012 0.99
65 Erectile dysfunction drug receipt, risky sexual behavior and sexually transmitted diseases in HIV-infected and HIV-uninfected men. J Gen Intern Med 2009 0.97
66 Treatment of adolescent opioid dependence: no quick fix. JAMA 2008 0.97
67 Nonmedical use of prescription opioids and pain in veterans with and without HIV. Pain 2011 0.97
68 Agreement between electronic medical record-based and self-administered pain numeric rating scale: clinical and research implications. Med Care 2013 0.97
69 Buprenorphine for office-based practice: consensus conference overview. Am J Addict 2004 0.96
70 Faculty development in small-group teaching skills associated with a training course on office-based treatment of opioid dependence. Subst Abus 2004 0.96
71 A randomized trial of primary intensive care to reduce hospital admissions in patients with high utilization of inpatient services. Dis Manag 2006 0.96
72 Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med 2012 0.95
73 Nonmedical use of opioid analgesics obtained directly from physicians: prevalence and correlates. Arch Intern Med 2011 0.95
74 Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr 2011 0.94
75 Hepatitis C and HIV infections: implications for clinical care in injection drug users. Am J Addict 2004 0.93
76 Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res 2011 0.92
77 Prevalence and correlates for nonmedical use of prescription opioids among urban and rural residents. Drug Alcohol Depend 2012 0.91
78 Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone. J Addict Med 2012 0.90
79 State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. J Gen Intern Med 2011 0.90
80 Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. J Acquir Immune Defic Syndr 2012 0.90
81 Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone. J Gen Intern Med 2010 0.90
82 The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 2011 0.90
83 Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med 2012 0.89
84 Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients. J Subst Abuse Treat 2012 0.89
85 Update in addiction medicine for the primary care clinician. J Gen Intern Med 2008 0.89
86 Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav 2010 0.89
87 Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians. J Addict Med 2012 0.88
88 Development of a scale to measure practitioner adherence to a brief intervention in the emergency department. J Subst Abuse Treat 2012 0.88
89 Combining rapid HIV testing and a brief alcohol intervention in young unhealthy drinkers in the emergency department: a pilot study. Am J Drug Alcohol Abuse 2012 0.87
90 The Recovery Line: A pilot trial of automated, telephone-based treatment for continued drug use in methadone maintenance. J Subst Abuse Treat 2013 0.86
91 Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment. Drug Alcohol Depend 2012 0.86
92 Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. J Acquir Immune Defic Syndr 2015 0.86
93 Evaluating interventions to improve antiretroviral adherence: how much of an effect is required for favorable value? Value Health 2010 0.85
94 Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine. Am J Prev Med 2013 0.84
95 Buprenorphine: effective treatment of opioid addiction starts in the office. Am Fam Physician 2006 0.83
96 Sex disparities in overall burden of disease among HIV-infected individuals in the Veterans Affairs healthcare system. J Gen Intern Med 2013 0.83
97 Primary intensive care: pilot study of a primary care-based intervention for high-utilizing patients. Dis Manag 2005 0.82
98 Instruments to assess patient-reported safety, efficacy, or misuse of current opioid therapy for chronic pain: a systematic review. Pain 2013 0.82
99 Update in addiction medicine for the generalist. J Gen Intern Med 2007 0.81
100 The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. J Acquir Immune Defic Syndr 2011 0.81
101 Source of prescription drugs used nonmedically in rural and urban populations. Am J Drug Alcohol Abuse 2014 0.80
102 Screening, brief intervention, and referral to treatment (SBIRT) for alcohol and other drug use among adolescents: evaluation of a pediatric residency curriculum. Subst Abus 2012 0.80
103 Antiretroviral adherence among rural compared to urban veterans with HIV infection in the United States. AIDS Behav 2013 0.80
104 Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. J Addict Med 2013 0.79
105 Methadone syrup injection in Australia: a sentinel finding? Addiction 2003 0.79
106 Mental health after deployment to Iraq or Afghanistan. JAMA 2006 0.79
107 Substance use in older HIV-infected patients. Curr Opin HIV AIDS 2014 0.79
108 Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. J Subst Abuse Treat 2007 0.79
109 Unobserved "home" induction onto buprenorphine. J Addict Med 2014 0.79
110 Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients. AIDS 2016 0.78
111 The case for routine HIV screening and impact of managed care. Am J Manag Care 2010 0.78
112 Substance use in patients with sexually transmitted infections: results from a national U.S. survey. Am J Addict 2010 0.78
113 Depression symptoms and treatment among HIV infected and uninfected veterans. AIDS Behav 2008 0.77
114 HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment. J Addict Med 2013 0.77
115 Prevalence of unhealthy substance use on teaching and hospitalist medical services: implications for education. Am J Addict 2012 0.77
116 Incarceration and health outcomes in HIV-infected patients: the impact of substance use, primary care engagement, and antiretroviral adherence. Am J Addict 2015 0.77
117 Opioid doses and increased risk for overdose. Ann Intern Med 2010 0.76
118 The Availability of Ancillary Counseling in the Practices of Physicians Prescribing Buprenorphine. J Addict Med 2016 0.75
119 Alcohol Use. Ann Intern Med 2016 0.75
120 The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality. J Addict Med 2016 0.75
121 Adding buprenorphine implants to counselling reduces opioid use over 6 months in opioid-dependent adults. Evid Based Ment Health 2011 0.75
122 Major depression and recent physical or sexual abuse increase readmissions among high-utilising primary care patients. Ment Health Fam Med 2008 0.75
123 Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis. Pharmacoepidemiol Drug Saf 2013 0.75
124 Initial development of patient-reported instrument assessing harm, efficacy, and misuse of long-term opioid therapy. J Rehabil Res Dev 2016 0.75
125 Clinical case conference: unobserved "home" induction onto buprenorphine. J Addict Med 2014 0.75
126 Long-term alcohol use patterns and HIV disease severity: A joint trajectory analysis. AIDS 2017 0.75
127 Alcohol Use. Ann Intern Med 2016 0.75
128 Assessing research activity and capacity of community-based organizations: development and pilot testing of an instrument. Prog Community Health Partnersh 2014 0.75
129 Racial/ethnic differences in report of drug testing practices at the workplace level in the U.S. Am J Addict 2013 0.75
130 Physician detection of unhealthy substance use on inpatient teaching and hospitalist medical services. Am J Drug Alcohol Abuse 2012 0.75
131 Connecticut statewide addiction medicine/psychiatry grand rounds. Conn Med 2003 0.75
132 Long-term alcohol use patterns and HIV disease severity. AIDS 2017 0.75